Permanens Capital L.P. bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,994 shares of the conglomerate's stock, valued at approximately $1,908,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. EP Wealth Advisors LLC acquired a new position in Danaher in the second quarter valued at approximately $3,807,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Danaher by 303.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate's stock valued at $56,777,000 after buying an additional 186,584 shares during the last quarter. Puzo Michael J purchased a new stake in Danaher in the second quarter valued at $8,624,000. Legal & General Group Plc lifted its holdings in shares of Danaher by 1.0% in the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate's stock valued at $1,029,061,000 after purchasing an additional 43,169 shares during the last quarter. Finally, Madison Asset Management LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at about $85,451,000. Institutional investors and hedge funds own 79.05% of the company's stock.
Danaher Price Performance
Shares of NYSE DHR opened at $215.90 on Thursday. The stock has a fifty day moving average price of $197.93 and a 200 day moving average price of $192.36. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $151.77 billion, a PE ratio of 38.35, a P/E/G ratio of 2.69 and a beta of 0.78.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher's quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 EPS. Sell-side analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.
Wall Street Analyst Weigh In
DHR has been the topic of several research analyst reports. TD Cowen cut their price target on Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a research report on Wednesday, July 22nd. Piper Sandler began coverage on shares of Danaher in a research report on Thursday, June 11th. They set a "neutral" rating and a $200.00 target price on the stock. DZ Bank initiated coverage on shares of Danaher in a report on Wednesday, June 3rd. They issued a "buy" rating and a $210.00 target price on the stock. Evercore reiterated an "outperform" rating and issued a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Finally, Wells Fargo & Company decreased their price target on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $228.91.
View Our Latest Stock Analysis on DHR
Danaher Profile
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
